1. Home
  2. Directory
  3. Texas
  4. Houston
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1336770940

DHARUSAL M PATEL MSN,APRN,FNP-C,PCCN
Prescription History 1336770940
Nurse Practitioner in Houston, TX


Quality Rating: 81.38 out of 100 score

NPI Status: Active since February 01, 2020

Contact Information

1515 HOLCOMBE BLVD
HOUSTON, TX
ZIP 77030
Phone: (713) 792-6161

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DHARUSAL M PATEL MSN,APRN,FNP-C,PCCN, an active Nurse Practitioner specialist practicing in Houston, TX. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 327 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 229 claims alone.

Medication Index

A
E
G
L
T
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 229
30-Day Fills 599.3
Days Supply 17,940
TX State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills155.7
Peer Average Days Supply4,650
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 252.3% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,449.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.16

State Avg Cost Per Claim

$24.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 44.0
Days Supply 1,320
TX State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills58.8
Peer Average Days Supply1,760
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,718.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$169.03

State Avg Cost Per Claim

$250.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Gabapentin

Generic Formulation: GabapentinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 337
TX State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills159.7
Peer Average Days Supply4,701
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.1% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $135.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.67

State Avg Cost Per Claim

$21.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 40
30-Day Fills 116.0
Days Supply 3,480
TX State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills128.1
Peer Average Days Supply3,830
Conservative Utilization

This provider writes prescriptions for this formulation 29.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,121.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.03

State Avg Cost Per Claim

$27.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 64.7
Days Supply 1,941
TX State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills88.8
Peer Average Days Supply2,658
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $793.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.07

State Avg Cost Per Claim

$34.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DHARUSAL M PATEL MSN,APRN,FNP-C,PCCN provides transparency into local medical care patterns within Houston, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.